ClinicalTrials.gg
Status unknownNCT03669965Updated Jul 31, 2020

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

A Phase 2 interventional study of KRT-232 and Ruxolitinib in Polycythemia Vera, sponsored by Kartos Therapeutics, Inc.. Status unknown at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-31.

Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 179 studies in Polycythemia Vera with a site in United States — 21 open to participants now, 33 under way, 7 of them phase 3. Polycythemia Vera · United States.

Enrollment
111th of 150
20 · median 40
Started
2019
with 6 others
Phase 2
68 of 179
6 open now
Registered
138th of 179
by date

Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 111th largest by enrollment of the 150 interventional ones that give a count, is one of 7 that started in 2019, is one of 68 in phase 2, and was the 138th registered.

Polycythemia Vera

279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

21 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Polycythemia Vera with a site in United States, or all of them as a file.
02

Study summary

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with phlebotomy-dependent polycythemia vera (PV). Inhibition of MDM2 in PV is a new mechanism of action in PV. In Part A, patients must be resistant or intolerant to hydroxyurea or have undergone treatment with interferon. In Part B, patients must be resistant or intolerant to hydroxyurea.

This study is a global, open-label Phase 2a/2b study to determine the efficacy and safety of KRT-232. In Part A of the study, patients will be randomly assigned to 5 arms with 2 different doses and 3 different dosing schedules of KRT 232. In Part B of the study, patients will be randomized either to treatment with KRT-232 administered at the recommended dose and schedule from Part A or to treatment with ruxolitinib.

03

Conditions studied

  • Polycythemia Vera

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of PV (WHO 2016)
  • ≤ 2
  • Part A: patients with and without splenomegaly are eligible
  • Part A: patients must be resistant or intolerant to hydroxyurea or have undergone treatment with interferon
  • Part B: only patients with splenomegaly are eligible
  • Part B: patients must be resistant or intolerant to hydroxyurea

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of post-PV myelofibrosis (IWG-MRT)
  • Prior treatment with MDM2 inhibitors, p53-directed therapies, HDAC, BCL 2 inhibitors
  • Splenic irradiation within 3 months prior to the first dose of study treatment
  • thrombosis within 3 months of screening
  • Grade 2 or higher prolongation
  • Part B: prior treatment with a JAK inhibitor
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Part A Arm 1

    KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)

    Drug: KRT-232

  • Experimental
    Part A Arm 2

    KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)

    Drug: KRT-232

  • Experimental
    Part A Arm 3

    KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)

    Drug: KRT-232

  • Experimental
    Part B KRT-232 Arm

    Recommended KRT-232 dose and schedule from Part A

    Drug: KRT-232

  • Active comparator
    Part B Ruxolitinib Arm

    Ruxolitinib per approved prescribing label

    Drug: Ruxolitinib

  • Experimental
    Part A Arm 4b

    KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)

    Drug: KRT-232

  • Experimental
    Part A Arm 2b

    KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)

    Drug: KRT-232

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients with splenomegaly achieving a response at Week 32

    Response defined as having achieved both of the following: * The absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32, with no more than one phlebotomy eligibility occurring post-randomization and prior to the Week 8 visit * A reduction in spleen volume as assessed by MRI (or CT) ≥ 35% from baseline at Week 32

    Time frame: 32 weeks

Secondary outcomes

  1. Duration of response after achieving both the absence of phlebotomy eligibility and reduction in spleen volume (for patients with splenomegaly)

    Time frame: 4 years

  2. Duration of response after achieving phlebotomy independence

    Time frame: 4 years

  3. Change from baseline of MPN-SAF TSS v2.0 patient-reported outcome

    Time frame: 32 weeks

  4. Change from baseline of EORTC-QLQ-C30 patient-reported outcome

    Time frame: 32 weeks

Other outcomes

  1. Proportion of patients without splenomegaly achieving the absence of phlebotomy eligibility beginning at the Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8

    Time frame: 28 weeks

07

Study locations

16 sites
  • The Kirklin Clinic of UAB Hospital
    Birmingham, Alabama 35249, United States
  • University of Southern California Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Center Hospitalier Universitaire d'Angers
    Angers, 49933 Cedex 09, France
  • Universitätsklinikum Aachen
    Aachen, Nordrhein-westfalen, Germany
  • Gemeinschaftspraxis Haematologie - Onkologie - Hauptstelle
    Dresden, Sachsen, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Sachsen, Germany
  • Stauferklinikum Schwäbisch Gmünd
    Mutlangen, 73557, Germany
  • Békés Megyei Központi Kórház Pándy Kálmán Tagkórház
    Gyula, 5700, Hungary
  • Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku
    Wrocław, Dolnoslaskie, Poland
  • Szpital Wojewódzki w Opolu
    Opole, 45-061, Poland
  • Hospital Universitario de Gran Canaria Doctor Negrin
    Las Palmas de Gran Canaria, LAS Palmas, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Apr 2022, 39 months after the start.

Of 43 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 135. This study's planned 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2018
First posted
Sep 13, 2018
StartActual
Jan 15, 2019
Primary completionEst.
Apr 2022
CompletionEst.
Oct 2022
Last update
Jul 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03669965
Responsible party
Sponsor
First posted
Sep 13, 2018
Start date
Jan 15, 2019
Primary completion
Apr 2022 (estimated)
Completion
Oct 2022 (estimated)
Last update
Jul 31, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navtemadlin

Start the discussion